Commonwealth Equity Services’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.95M | Sell |
9,815
-762
| -7% | -$230K | ﹤0.01% | 1787 |
|
|
2026
Q1 | $3.5M | Buy |
10,577
+832
| +9% | +$283K | ﹤0.01% | 1592 |
|
|
2025
Q4 | $3.87M | Buy |
9,745
+338
| +4% | +$150K | 0.01% | 1502 |
|
|
2025
Q3 | $4.29M | Sell |
9,407
-519
| -5% | -$211K | 0.01% | 1458 |
|
|
2025
Q2 | $3.24M | Buy |
9,926
+1,455
| +17% | +$403K | ﹤0.01% | 1643 |
|
|
2025
Q1 | $2.29M | Buy |
8,471
+1,934
| +30% | +$497K | ﹤0.01% | 1819 |
|
|
2024
Q4 | $1.54M | Buy |
6,537
+1,234
| +23% | +$325K | ﹤0.01% | 2055 |
|
|
2024
Q3 | $1.46M | Sell |
5,303
-449
| -8% | -$117K | ﹤0.01% | 2046 |
|
|
2024
Q2 | $1.4M | Buy |
5,752
+158
| +3% | +$24.9K | ﹤0.01% | 2034 |
|
|
2024
Q1 | $836K | Buy |
5,594
+1,365
| +32% | +$228K | ﹤0.01% | 2377 |
|
|
2023
Q4 | $809K | Sell |
4,229
-143
| -3% | -$24.4K | ﹤0.01% | 2319 |
|
|
2023
Q3 | $774K | Buy |
4,372
+363
| +9% | +$69.3K | ﹤0.01% | 2250 |
|
|
2023
Q2 | $761K | Buy |
4,009
+348
| +10% | +$69K | ﹤0.01% | 2298 |
|
|
2023
Q1 | $733K | Sell |
3,661
-1,546
| -30% | -$325K | ﹤0.01% | 2258 |
|
|
2022
Q4 | $1.24M | Buy |
5,207
+433
| +9% | +$92.4K | ﹤0.01% | 1820 |
|
|
2022
Q3 | $955K | Buy |
4,774
+198
| +4% | +$37.8K | ﹤0.01% | 1929 |
|
|
2022
Q2 | $667K | Sell |
4,576
-442
| -9% | -$62.7K | ﹤0.01% | 2206 |
|
|
2022
Q1 | $819K | Sell |
5,018
-193
| -4% | -$29.4K | ﹤0.01% | 2140 |
|
|
2021
Q4 | $883K | Buy |
5,211
+942
| +22% | +$175K | ﹤0.01% | 2084 |
|
|
2021
Q3 | $806K | Sell |
4,269
-103
| -2% | -$19.3K | ﹤0.01% | 2091 |
|
|
2021
Q2 | $741K | Sell |
4,372
-444
| -9% | -$65K | ﹤0.01% | 2153 |
|
|
2021
Q1 | $679K | Buy |
4,816
+476
| +11% | +$71.6K | ﹤0.01% | 2080 |
|
|
2020
Q4 | $564K | Sell |
4,340
-7
| -0.2% | -$935 | ﹤0.01% | 2070 |
|
|
2020
Q3 | $632K | Buy |
4,347
+133
| +3% | +$18.9K | ﹤0.01% | 1808 |
|
|
2020
Q2 | $624K | Buy |
4,214
+84
| +2% | +$11.3K | ﹤0.01% | 1731 |
|
|
2020
Q1 | $449K | Sell |
4,130
-1,470
| -26% | -$170K | ﹤0.01% | 1764 |
|
|
2019
Q4 | $644K | Sell |
5,600
-1,459
| -21% | -$145K | ﹤0.01% | 1715 |
|
|
2019
Q3 | $567K | Sell |
7,059
-37
| -0.5% | -$2.93K | ﹤0.01% | 1736 |
|
|
2019
Q2 | $514K | Buy |
7,096
+76
| +1% | +$5.83K | ﹤0.01% | 1775 |
|
|
2019
Q1 | $656K | Sell |
7,020
-2,051
| -23% | -$172K | ﹤0.01% | 1567 |
|
|
2018
Q4 | $661K | Buy |
9,071
+5,802
| +177% | +$446K | ﹤0.01% | 1459 |
|
|
2018
Q3 | $286K | Buy |
3,269
+206
| +7% | +$20.7K | ﹤0.01% | 2209 |
|
|
2018
Q2 | $302K | Buy |
3,063
+100
| +3% | +$9.92K | ﹤0.01% | 2116 |
|
|
2018
Q1 | $352K | Sell |
2,963
-2,910
| -50% | -$375K | ﹤0.01% | 1945 |
|
|
2017
Q4 | $746K | Sell |
5,873
-1,159
| -16% | -$146K | ﹤0.01% | 1406 |
|
|
2017
Q3 | $826K | Sell |
7,032
-267
| -4% | -$22.8K | ﹤0.01% | 1294 |
|
|
2017
Q2 | $582K | Buy |
7,299
+895
| +14% | +$57.2K | ﹤0.01% | 1468 |
|
|
2017
Q1 | $328K | Sell |
6,404
-180
| -3% | -$8.32K | ﹤0.01% | 1788 |
|
|
2016
Q4 | $247K | Buy |
6,584
+780
| +13% | +$32.7K | ﹤0.01% | 1916 |
|
|
2016
Q3 | $393K | Buy |
5,804
+100
| +2% | +$7.05K | ﹤0.01% | 1528 |
|
|
2016
Q2 | $317K | Buy |
+5,704
| New | +$359K | ﹤0.01% | 1623 |
|
Other funds holding ALNY
Commonwealth Equity Services's ALNY Position: Q2 2026 in Review
Commonwealth Equity Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 7.2% in Q2 2026, selling an estimated $230K and leaving 9,815 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1787.
Commonwealth Equity Services first reported a position in ALNY in Q2 2016 and has held it in 41 quarters since. The position peaked at $4.29M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Commonwealth Equity Services held 9,815 shares of Alnylam Pharmaceuticals worth $2.95M as of Q2 2026.
- Commonwealth Equity Services sold 762 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $230K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #1787 holding.
- Commonwealth Equity Services first reported a position in Alnylam Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- Commonwealth Equity Services's Alnylam Pharmaceuticals position peaked at $4.29M in Q3 2025.
- 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.